Agilent Technologies, Inc. · NYSE:A
Agilent Technologies — Q3 2025 Earnings Presentation
12 slides from Agilent Technologies's earnings presentation, Aug 27, 2025
Slide 1: 3Q FY2025 Financial Results Overview
3Q FY2025 FINANCIAL RESULTS OVERVIEW Aug. 27, 2025
Slide 2: Safe Harbor
Thank You for Your Attention Safe Harbor This presentation contains forward- successfully adapt its cost structures to The company assumes no obligation to looking statements (including, without continuing changes in business update the information in these limitation, information, and future condit
Slide 3: Revenue Beat, EPS at High End; FY25 Core Growth Outlook Increased
Agilent 3Q25 Results Revenue Beat, EPS at High End; FY25 Core Growth(1) Outlook Increased $ • Revenue $1.74B, exceeded top of guidance by more Revenue Operating Margin EPS than $60M despite dynamic market conditions • EPS $1.37(2), +4% YoY, at the high end of guidance $1.74B 25.1% (2) $1.37 (2) +10.
Slide 4: Growth Momentum
Growth Momentum $1.74B +10.1% +6.1% five consecutive quarters of (1)(2) Q3 Reported Revenue Q3 Reported Growth Q3 Core Growth accelerating core growth(1) FY25 Outlook 4Q25 Outlook 4.5% 5.4% Core Growth(1) at Core Growth(1) at midpoint of range midpoint of range Up +150 bps Q4 sustaining 2Yr core vs
Slide 5: Delivered Growth in Q3 Led by LDG
All Segments LDG +7% • LC & LC/MS strong Core Growth(1)(2) • CDMO (siRNA, GLP-1) drives 17.6% growth Delivered Operating Margin(2) +14% Reported Growth in Q3 Led by LDG ACG +5% • Services & Consumables solid • China tariff pull-forward impact All three segments Core Growth(1)(2) 33.3% absorbed excee
Slide 6: Broad-Based Growth Across All Major Regions
GEOGRAPHY PRODUCT TYPE Broad-Based Growth Americas 39% of Agilent Revenue(2) Across All Major 7% (1) 7% (1) Europe 5% (1) Regions 28% of Agilent Revenue(2) GROWTH GROWTH GROWTH Asia-Pacific 33% of Agilent Revenue(2) (1) Core growth is reported growth adjusted for the effects of acquisitions and dive
Slide 7: Q3 revenue mix
GEOGRAPHY PRODUCT TYPE % of total revenue Q3 revenue mix 66% Consumables Services Consumables, services, & Informatics informatics up 100 bps 34% year-over-year Instruments 07
Slide 8: Broad-Based End-Market Growth, Led by Pharma and Chemicals & Advanced Materials
Q3 Core Share Growth(1) of Agilent Results Revenue(2) Excellent growth the result of strong portfolio and team Pharma on improving capital spending environment +9% 36% Q3 REVENUE Academia & China and resilient services and consumables offsets Broad-Based Government expected weak instrument spending
Slide 9: Innovation Pipeline Driving Growth
IGNITE Innovation Pipeline Driving 01 02 03 Infinity III Pro IQ Dako Growth LC LC/MS Omnis Family Delivering workflow excellence and Next Gen HPLC Single-quad LC/MS Automated IHC & productivity gains ISH Cancer Dx strong adoption, mid-teens enables fully-automated ahead of launch forecast, growth, c
Slide 10: Raised FY25 Guidance on Strong Q3 Momentum
Net Raised FY25 Revenue ($M) $6,910 $6,930 Revenue Guidance Core Revenue +4.3% +4.6% Growth(2) on Strong Q3 -0.1% FX +2.0% M&A Momentum (1) EPS $5.56 $5.59 Net Interest + $1.5-1.6B Operating $26M Other Inc/(Exp) $282M Dividends FY25 FY25 Cash Flow FY25 Anti-dilutive $450M CapEx 285M Share share repu
Slide 11: Q4 25 Guidance
Net Revenue ($M) $1,822 $1,842 Q425 guidance (1) Core Revenue +4.8% +6.0% Volume driving Growth(2) +0.2% FX, +2.1% M&A margin expansion EPS $1.57 $1.60 Net Interest + Anti-dilutive $9M Other Inc/(Exp) 284M Share Count share repurchases Q4 Q4 at a minimum(3) (1) As of August 27, 2025, based on foreca
Slide 12: Get in touch with us
Get in touch with us Trusted Answers investor_relations@agilent.com www.investor.agilent.com